دورية أكاديمية
Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
| العنوان: | Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. |
|---|---|
| المؤلفون: | Stanford JL; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA., Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA |
| المصدر: | JAMA [JAMA] 1995 Jul 12; Vol. 274 (2), pp. 137-42. |
| نوع المنشور: | Journal Article; Research Support, U.S. Gov't, P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Print ISSN: 0098-7484 (Print) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Chicago : American Medical Association, 1960- |
| مواضيع طبية MeSH: | Breast Neoplasms/*epidemiology , Estrogen Replacement Therapy/*adverse effects , Estrogens/*adverse effects , Progestins/*adverse effects, Breast Neoplasms/chemically induced ; Case-Control Studies ; Drug Therapy, Combination ; Estrogens/therapeutic use ; Female ; Humans ; Logistic Models ; Middle Aged ; Progestins/therapeutic use ; Proportional Hazards Models ; Risk Factors |
| مستخلص: | Objective: To determine the risk of breast cancer in relation to the use of combined estrogen and progestin hormone replacement therapy (HRT). Design: A population-based case-control study. Setting: The general female population of King County in western Washington State. Participants: Middle-aged (50 to 64 years) women, including 537 patients with incident primary breast cancer diagnosed between January 1, 1988, and June 30, 1990, who were ascertained through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry and 492 randomly selected control women without a history of breast cancer. Main Outcome Measure: Breast cancer risk in relation to use of menopausal hormones. Results: Menopausal hormones of some type had been used by 57.6% of breast cancer cases and 61.0% of comparison women. The women who had ever taken combined estrogen-progestin HRT, representing 21.5% of cases and 21.3% of controls, were not at increased risk of breast cancer (relative odds [RO] = 0.9; 95% confidence interval [CI], 0.7 to 1.3). Compared with nonusers of menopausal hormones, those who used estrogen-progestin HRT for 8 or more years had, if anything, a reduced risk of breast cancer (RO = 0.4; 95% CI, 0.2 to 1.0). Conclusions: On the whole, the use of estrogen with progestin HRT does not appear to be associated with an increased risk of breast cancer in middle-aged women. Nonetheless, since the use of combined estrogen-progestin HRT has only recently become prevalent, future investigations must assess whether breast cancer incidence is altered many years after estrogen-progestin HRT has been initiated, particularly among long-term users. |
| التعليقات: | Comment in: ACP J Club. 1996 Jan-Feb;124(1):21. Comment in: JAMA. 1995 Jul 12;274(2):178-9. (PMID: 7596008) Comment in: JAMA. 1996 Apr 17;275(15):1159-60. (PMID: 8609680) |
| معلومات مُعتمدة: | K07-CA01364 United States CA NCI NIH HHS; N01-CN-05230 United States CN NCI NIH HHS; R35-CA39779 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Estrogens) 0 (Progestins) |
| تواريخ الأحداث: | Date Created: 19950712 Date Completed: 19950731 Latest Revision: 20161017 |
| رمز التحديث: | 20240829 |
| PMID: | 7596001 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0098-7484 |
|---|